Akero Therapeutics, Inc. (AKRO) has 151 open-market insider trades by 20 insiders since 2019. The most active filer is Andrew Cheng, CEO & President.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Skorpios Trust | — | — | 1 | $71.2M | 2022-12-01 |
| Seth Loring Harrison | Dir | — | 5 | $59.4M | 2025-12-09 |
| G. Walmsley Graham | Dir | — | 8 | $50.2M | 2025-12-09 |
| Versant Venture Capital VI, L.P. | 10% Owner | — | 4 | $17.0M | 2019-12-31 |
| Corey S. Goodman | 10% Owner | — | 4 | $16.9M | 2020-03-06 |
| Andrew Cheng | CEOPres | — | 26 | $13.0M | 2025-12-09 |
| venBio Global Strategic Fund II L.P. | 10% Owner | — | 4 | $11.2M | 2020-07-06 |
| Timothy Rolph | CSO | — | 15 | $9.9M | 2025-12-09 |
| William Richard White | CFO | — | 22 | $7.1M | 2025-12-09 |
| Catriona Yale | — | — | 19 | $5.9M | 2025-12-09 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Andrew Cheng | CEO & President | Sell | $1.6M | 2025-10-10 |
| Timothy Rolph | CSO | Sell | $1.1M | 2025-10-07 |
| Jonathan Young | COO | Sell | $1.2M | 2025-10-01 |
| Timothy Rolph | Chief Scientific Officer | Sell | $24K | 2025-09-11 |
| Jonathan Young | COO | Sell | $25K | 2025-09-11 |
| Catriona Yale | Chief Development Officer | Sell | $28K |
Companies that share insiders with AKRO, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2025-09-11 |
| Andrew Cheng | CEO & President | Sell | $2.4M | 2025-09-10 |
| Timothy Rolph | CSO | Sell | $1.1M | 2025-09-08 |
| Jonathan Young | COO | Sell | $705K | 2025-09-02 |
| Jane Henderson | Director | Sell | $142K | 2025-08-12 |
| Jonathan Young | COO | Sell | $1.2M | 2025-08-12 |
| Andrew Cheng | CEO & President | Sell | $2.9M | 2025-08-11 |
| Timothy Rolph | CSO | Sell | $1.2M | 2025-08-05 |
| Catriona Yale | — | Sell | $1.1M | 2025-07-16 |
| Andrew Cheng | CEO & President | Sell | $3.1M | 2025-07-10 |